Stocks and Investing Stocks and Investing
Fri, March 31, 2023

Eliana Merle Maintained (BNTX) at Hold with Decreased Target to $153 on, Mar 31st, 2023


Published on 2024-10-28 02:31:05 - WOPRAI, Eliana Merle
  Print publication without navigation


Eliana Merle of UBS, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $168 to $153 on, Mar 31st, 2023.

Eliana has made no other calls on BNTX in the last 4 months.



There are 8 other peers that have a rating on BNTX. Out of the 8 peers that are also analyzing BNTX, 5 agree with Eliana's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Yaron Werber of "TD Cowen" Maintained at Hold with Decreased Target to $130 on, Tuesday, March 28th, 2023
  • Matthew Korn of "Morgan Stanley" Maintained at Hold with Decreased Target to $150 on, Tuesday, March 28th, 2023
  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Decreased Target to $140 on, Tuesday, March 28th, 2023
  • Jessica Fye of "JP Morgan" Maintained at Hold with Decreased Target to $142 on, Wednesday, February 8th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $216 on, Tuesday, January 24th, 2023


These are the ratings of the 3 analyists that currently disagree with Eliana


  • Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $210 on, Thursday, March 30th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $194 on, Tuesday, March 28th, 2023
  • Bill Selesky of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $203 on, Tuesday, March 28th, 2023
Contributing Sources